Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar Life Science Investing
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 Life Science Investing
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements Life Science Investing
Cizzle Brands Corporation Announces Closing of Transformative Transaction with the Acquisition of Flow Water Inc.'s Co-Manufacturing Business Biotech Investing
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration Life Science Investing
Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025 Life Science Investing
